DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

H.C. Wainwright Downgrades SpringWorks Therapeutics to Neutral, Maintains $40 Price Target

H.C. Wainwright analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and maintains $40 price target.

Benzinga · 03/04/2020 12:44

H.C. Wainwright analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and maintains $40 price target.